Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling.

Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling.

The diagnostic of Amyotrophic lateral sclerosis (ALS) remains based on clinical and neurophysiological observations. The actual delay between the onset of the symptoms and diagnosis is about 1 year, preventing early inclusion of patients into clinical trials and early care of the disease. Therefore,...

Full description

Bibliographic Details
Main Authors: Laurence Conraux, Catherine Pech, Halim Guerraoui, Denis Loyaux, Pascual Ferrara, Jean-Claude Guillemot, Vincent Meininger, Pierre-François Pradat, François Salachas, Gaëlle Bruneteau, Nadine Le Forestier, Lucette Lacomblez
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24224000/?tool=EBI

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24224000/?tool=EBI

Similar Items